Related Experiment Video
Updated: Jun 17, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
Anti-LAG-3 boosts CD8 T cell effector function
Courtney T Kureshi1, Michael Dougan2, Stephanie K Dougan1
1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Program in Immunology, Harvard Medical School, Boston, MA, USA.
Abstract:
LAG-3 is the third immune checkpoint pathway successfully targeted for cancer therapy. Although ineffective as a monotherapy, combination of LAG-3 and PD-1 blockade improves survival from advanced melanoma. In this issue of Cell, two studies in mice and a human clinical trial provide insights on LAG-3 in immune regulation.
Insights
Immune checkpoint blockade targeting Lymphocyte-activation gene 3 (LAG-3) combined with PD-1 improves advanced melanoma survival. New research in mice and humans offers key insights into LAG-3
Area of Science:
- Immunology
- Oncology
- Cancer Immunotherapy
Background:
- Lymphocyte-activation gene 3 (LAG-3) is an emerging immune checkpoint target in cancer.
- LAG-3 blockade alone shows limited efficacy in cancer treatment.
Purpose of the Study:
- To investigate the role of LAG-3 in immune regulation.
- To evaluate the efficacy of combining LAG-3 and PD-1 blockade in cancer therapy.
Main Methods:
- Preclinical studies using mouse models.
- Analysis of a human clinical trial data.
Main Results:
- Combination therapy of LAG-3 and PD-1 blockade significantly improves survival in advanced melanoma.
- Studies provide novel insights into the immunoregulatory functions of LAG-3.
Conclusions:
- LAG-3 is a promising therapeutic target, particularly in combination regimens.
- Targeting LAG-3 alongside PD-1 enhances anti-tumor immune responses and clinical outcomes.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

